sunitinib + bevacizumab + sorafenib

Sunitinib, bevacizumab, and sorafenib are three distinct anti-cancer agents frequently used in the management of advanced cancers, particularly metastatic renal cell carcinoma (mRCC). Sunitinib and sorafenib are small molecule tyrosine kinase inhibitors that target multiple kinases involved in tumor proliferation and angiogenesis. Sunitinib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), c-Kit, Flt3, RET, and CSF1R. Sorafenib inhibits CRAF, BRAF, VEGFRs 1–3, PDGFR-beta, RET, Flt3, and c-Kit. Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor A (VEGF-A), preventing it from activating its receptors on the surface of endothelial cells and thereby inhibiting angiogenesis. These drugs have been studied both as monotherapies and in various combinations for their synergistic effects on blocking tumor blood vessel formation. Their primary indication is metastatic renal cell carcinoma; they are also investigated or used for other solid tumors[2][5][6][8].

Brand names

Nexavar

Other names

sunitinib malatesorafenib tosylate